TriangleInotuzumab Ozogamicin (NCT01371630)
Inotuzumab Ozogamicin trial for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (NCT01371630). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Acute lymphoblastic leukemia after sixty is a different disease. The intensive chemotherapy that cures children is often more than an older body can bear.
The idea: lower the chemotherapy, and add targeted drugs that do the heavy lifting.
At MD Anderson, patients receive a reduced-dose version of the standard regimen, mini-hyper-CVD, together with inotuzumab, an antibody that carries a potent toxin into leukemia cells marked CD22, and blinatumomab, which links T cells directly to leukemia cells.
In fifty-two patients with a median age of sixty-eight, fifty-nine percent were alive without progression at two years, though infections and low platelets were common and some deaths were treatment-related.
Elias Jabbour leads it; relapsed disease is now included. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.